46 completed, 17 unknown, 4 recruiting, 2 active not recruiting. 35 Phase 1, 11 Phase 2, 9 Phase 3, 8 Not applicable, 5 Phase 4.
By phase and status
Phase Trials Status Phase 1 35 Completed 23 , Unknown 10 , Not yet recruiting 1 , Recruiting 1 Phase 2 11 Completed 5 , Unknown 3 , Active not recruiting 1 , Not yet recruiting 1 , Withdrawn 1 Phase 3 9 Completed 7 , Active not recruiting 1 , Unknown 1 Not applicable 8 Completed 6 , Terminated 2 Phase 4 5 Completed 2 , Active not recruiting 1 , Recruiting 1 , Unknown 1 Early Phase 1 1 Completed 1
Follow LG Chem: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer Phase 1 / Phase 2 Not yet recruiting LG Chem 250 2026-12-01 2026-08-07 A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty Leuprorelin - Central Precocious Puberty Phase 4 Recruiting LG Chem 43 2026-08-01 2026-07-29 The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg - Healthy, Fasting Phase 1 Completed LG Chem 28 2026-06-11 2026-09-10 A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting. Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg, Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg - Healthy Volunteers, Fasting Conditions Phase 1 Completed LG Chem 58 2026-01-09 2026-07-24 A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg, Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg - Fed Conditions, Healthy Volunteer Phase 1 Completed LG Chem 50 2025-09-29 2026-01-12 A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus Phase 2 / Phase 3 Active not recruiting LG Chem 1186 2025-05-30 2026-09-03 Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET). Fang Le Shu (Follitrope), Guo Na Fen (Gonal-F) - Female Infertility Phase 4 Active not recruiting LG Chem 248 2025-02-15 2026-09-02 A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability Test Drug (Eutropin Catridge, 48IU/Cartridge), Reference Drug (Eutropin, 4 IU/vial) - Healthy Volunteers Phase 1 Completed LG Chem 48 2025-01-13 2025-04-17 Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus Phase 2 Unknown LG Chem 336 2024-10-02 2024-10-01 Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab - Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC) Phase 1 Recruiting LG Chem 76 2024-06-05 2025-11-24 Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) - Hyperphosphatemia Recruiting LG Chem 172 2023-12-21 2026-09-03 A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity LB54640 - POMC Deficiency Obesity, PCSK1 Deficiency Obesity Phase 2 Unknown LG Chem 4 2023-12-01 2023-11-02 Effect of Tigulixostat on the Pharmacokinetics of Theophylline Tigulixostat, Theophylline - Gout, Hyperuricemia Phase 1 Completed LG Chem 24 2023-10-31 2024-01-03 Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients Type 2 Diabetes Mellitus Completed LG Chem 2044 2023-10-26 2026-03-11 A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus Phase 1 Unknown LG Chem 42 2023-07-17 2023-07-19 Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia Phase 3 Completed LG Chem 2202 2023-03-30 2025-07-22 Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants Eupolio - Poliomyelitis, Vaccine Reaction Phase 3 Completed LG Chem 2001 2023-01-10 2025-04-06 Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Tigulixostat, Placebo - Gout, Hyperuricemia Phase 3 Completed LG Chem 354 2022-10-25 2025-10-29 A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA LG00034053 - Osteoarthritis, Knee Phase 1 / Phase 2 Completed LG Chem 74 2022-04-27 2024-05-03 A Study of LC542019 in Healthy Subjects and Subjects With T2DM LC542019, Placebo - Healthy, Diabetes Mellitus, Type 2 Phase 1 Completed LG Chem 100 2022-03-25 2024-03-27
Showing 20 of 73. Sign in to see all of them.
Conditions studied Diabetes Mellitus, Type 2 (11) · Gout (10) · Hyperuricemia (10) · Poliomyelitis (8) · Diphtheria (7) · Haemophilus Infections (7) · Hepatitis B (7) · Tetanus (7) · Whooping Cough (7) · Infertility, Female (3) · Carcinoma, Non-Small-Cell Lung (2) · Colitis, Ulcerative (2) · Pneumococcal Infections (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1)
Interventions LC15-0444 (11) · dapagliflozin (8) · Metformin (7) · Poliovirus Vaccine, Inactivated (4) · Drug Evaluation (3) · Vaccines, Combined (3) · Rosuvastatin Calcium (2) · Valsartan (2) · Allopurinol (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Continuous Glucose Monitoring (1) · Dipeptidyl-Peptidase IV Inhibitors (1) · Ezetimibe (1) · Human Growth Hormone (1) · Leuprolide (1)
Countries South Korea (28) · United States (14) · China (6) · Thailand (6) · Philippines (5) · Germany (4) · Poland (3) · Australia (2) · France (2) · Georgia (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1)
Top investigators Hyungjin Cho, MD (3) · Uthai Suvanakoot (2) · BK Lim, M.D. (1) · BK Suh, M.D. (1) · CH Shin, M.D. (1) · CJ Kim, M.D. (1) · CW Ko, M.D. (1) · CY Kim, M.D. (1) · DH Kim, M.D. (1) · DH Lee, M.D. (1) · DK Jin, M.D. (1) · DY Lee, M.D. (1) · EK Yoo, M.D. (1) · EY Kim, M.D. (1) · Edison Alberto, MD (1)
Results publications PMID 39929260 , PMID 30249366 , PMID 32274380 , PMID 32419399 , PMID 32980184 , PMID 33351072 , PMID 34192989 , PMID 35315601 , PMID 35472208 , PMID 38595129 , PMID 39676465 , PMID 39901524 , PMID 41493505